A new staging system for cardiac transthyretin amyloidosis
Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Philip N. Hawkins(The Royal Free Hospital), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Mathew D. Hutchinson(Children's Cancer and Leukaemia Group), Tamer Rezk(Boston University), Janet A. Gilbertson(Children's Cancer and Leukaemia Group), Marianna Fontana(Johnson & Johnson (United States)), Carol Whelan(Boston University), Thibaud Damy(Amyloidosis Foundation), Candida Cristina Quarta(Boston University), Esther González-López(Children's Cancer and Leukaemia Group), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Aviva Petrie(Eastman Dental Hospital), Thirusha Lane(Boston University), Dorota Rowczenio(Children's Cancer and Leukaemia Group)
Cited by 740
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k